Vaxil Historical Financial Ratios
| VXL Stock | CAD 0.01 0.00 0.00% |
Vaxil Bio is promptly reporting on over 87 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0, PTB Ratio of 2.9 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Vaxil Bio financial condition quickly.
Vaxil |
About Vaxil Financial Ratios Analysis
Vaxil BioFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Vaxil Bio investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Vaxil financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Vaxil Bio history.
Vaxil Bio Financial Ratios Chart
Add Fundamental
Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to Vaxil Bio. There are two different methods for calculating Vaxil Bio invested capital: operating approach and financing approach. Understanding Vaxil Bio invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Research And Ddevelopement To Revenue
The ratio of a company's research and development expenses to its total revenue, indicating how much of the revenue is invested back into developing new products or services.Most ratios from Vaxil Bio's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Vaxil Bio current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Vaxil Bio's Income Quality is fairly stable compared to the past year. Net Debt To EBITDA is likely to climb to 3.88 in 2024, whereas Book Value Per Share is likely to drop 0.01 in 2024.
| 2023 | 2024 (projected) | Payables Turnover | 5.84 | 5.55 | Days Of Inventory On Hand | 80.9K | 71.9K |
Vaxil Bio fundamentals Correlations
Click cells to compare fundamentals
Vaxil Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vaxil Bio fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | (5.34) | 37.96 | 6.0 | 2.41 | 3.84 | 2.9 | |
| Book Value Per Share | (0.006556) | 0.007903 | 0.0125 | 0.008293 | 0.006504 | 0.006178 | |
| Free Cash Flow Yield | (0.19) | (0.0361) | (0.11) | (0.27) | (0.16) | (0.17) | |
| Operating Cash Flow Per Share | (0.006702) | (0.0108) | (0.007965) | (0.005358) | (0.004095) | (0.0043) | |
| Pb Ratio | (5.34) | 37.96 | 6.0 | 2.41 | 3.84 | 2.9 | |
| Free Cash Flow Per Share | (0.006702) | (0.0108) | (0.007965) | (0.005358) | (0.004095) | (0.0043) | |
| Roic | 1.71 | (1.69) | (0.58) | (0.51) | (0.29) | (0.3) | |
| Net Income Per Share | (0.0123) | (0.0131) | (0.0135) | (0.007245) | (0.004263) | (2.0E-6) | |
| Payables Turnover | 0.21 | 0.0969 | 44.72 | 5.08 | 5.84 | 5.55 | |
| Cash Per Share | 9.33E-4 | 0.0148 | 0.0165 | 0.011 | 0.006847 | 0.006504 | |
| Pocfratio | (5.22) | (27.67) | (9.42) | (3.73) | (6.11) | (6.41) | |
| Pfcf Ratio | (5.22) | (27.67) | (9.42) | (3.73) | (6.11) | (6.41) | |
| Days Payables Outstanding | 1.7K | 3.8K | 8.16 | 71.91 | 82.69 | 78.56 | |
| Income Quality | 0.52 | 0.81 | 1.1 | 1.26 | 2.21 | 2.32 | |
| Roe | 2.0 | (1.7) | (0.58) | (0.51) | (2.85E-4) | (2.99E-4) | |
| Ev To Operating Cash Flow | (5.11) | (26.31) | (7.35) | (1.68) | (4.43) | (4.65) | |
| Pe Ratio | (2.67) | (22.29) | (10.35) | (4.69) | (13.5K) | (12.8K) | |
| Return On Tangible Assets | (5.68) | (0.82) | (0.43) | (0.38) | (2.6E-4) | (2.73E-4) | |
| Ev To Free Cash Flow | (5.11) | (26.31) | (7.35) | (1.68) | (4.43) | (4.65) | |
| Earnings Yield | (0.37) | (0.0449) | (0.0966) | (0.21) | (7.4E-5) | (7.8E-5) | |
| Net Debt To E B I T D A | 0.0633 | 1.16 | 2.33 | 2.59 | 3.69 | 3.88 | |
| Current Ratio | 1.82 | 0.14 | 1.91 | 3.9 | 3.8 | 12.06 | |
| Tangible Book Value Per Share | (0.006556) | 0.007903 | 0.0125 | 0.008293 | 0.006504 | 0.006178 | |
| Graham Number | 0.044 | 0.0489 | 0.0451 | 0.0282 | 5.21E-4 | 4.95E-4 | |
| Shareholders Equity Per Share | (0.006556) | 0.007903 | 0.0125 | 0.008293 | 0.006504 | 0.006178 | |
| Graham Net Net | (0.007835) | 0.006662 | 0.0124 | 0.008176 | 0.00633 | 0.006014 | |
| Enterprise Value Over E B I T D A | (2.92) | (22.5) | (8.29) | (2.11) | (9.79) | (9.3) | |
| Price Earnings Ratio | (2.67) | (22.29) | (10.35) | (4.69) | (13.5K) | (12.8K) | |
| Price Book Value Ratio | (5.34) | 37.96 | 6.0 | 2.41 | 3.84 | 2.9 | |
| Price Earnings To Growth Ratio | (0.41) | (7.3) | 0.22 | 0.12 | 134.84 | 141.59 | |
| Days Of Payables Outstanding | 1.7K | 3.8K | 8.16 | 71.91 | 82.69 | 78.56 | |
| Price To Operating Cash Flows Ratio | (5.22) | (27.67) | (9.42) | (3.73) | (6.11) | (6.41) | |
| Price To Free Cash Flows Ratio | (5.22) | (27.67) | (9.42) | (3.73) | (6.11) | (6.41) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxil Stock Analysis
When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.